Clinical Trial Update: Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of dalutrafusp alfa (GS-1423) in participants with advanced solid tumors has been terminated after results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• dalutrafusp alfa (dalutrafusp alfa)

Snippet

Sponsor: Gilead Sciences | Conditions: Advanced Solid Tumors | Phase 1 | Status: TERMINATED | Results posted: 2023-11-21